DBV Technologies SA – (NASDAQ:DBVT) shares saw strong trading volume on Tuesday . 90,736 shares changed hands during mid-day trading, an increase of 27% from the previous session’s volume of 71,524 shares.The stock last traded at $34.98 and had previously closed at $34.56.

A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of DBV Technologies SA – from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Jefferies Group restated a “buy” rating on shares of DBV Technologies SA – in a research report on Wednesday, June 8th. Finally, Leerink Swann restated a “buy” rating on shares of DBV Technologies SA – in a research report on Tuesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $50.52.

The company’s market cap is $1.61 billion. The stock has a 50-day moving average price of $34.03 and a 200 day moving average price of $31.60.

Several large investors recently bought and sold shares of DBVT. New York State Common Retirement Fund bought a new stake in DBV Technologies SA – during the fourth quarter worth $2,551,000. Jennison Associates LLC increased its stake in DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock worth $26,208,000 after buying an additional 6,578 shares during the last quarter. Finally, RS Investment Management Co. LLC increased its stake in DBV Technologies SA – by 1.7% in the fourth quarter. RS Investment Management Co. LLC now owns 502,860 shares of the company’s stock worth $18,259,000 after buying an additional 8,220 shares during the last quarter.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.